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Gastrointestinal oncology is one of the foremost causes of death: the gastric cancer accounts for 10.4% of cancer deaths worldwide,
the pancreatic cancer for 6%, and ﬁnally, the colorectal cancer for 9% of all cancer-related deaths. For all these gastrointestinal
cancers, surgical tumor resection remains the primary curative treatment, but the overall 5-year survival rate remains poor,
rangingbetween20–25%;theadditionofcombinedmodalitystrategies(pre-orpostoperativechemoradiotherapyorperioperative
chemotherapy) results in 5-year survival rates of only 30–35%. Therefore, many investigators believe that the potential for making
signiﬁcant progress lies on understanding and exploiting the molecular biology of gastrointestinal tumors to investigate new
therapeutic strategies such as speciﬁc immunotherapy. In this paper we will focus on recent knowledge concerning the role of
T cells and the use of T adoptive immunotherapy in the treatment of gastrointestinal cancers.
1.Introduction
Gastrointestinal oncology is one of the foremost causes
of death; regarding the gastric cancer (GC) the American
Cancer Society estimated one million new cases, nearly
70% of them in developing countries, and about 800,000
deaths [1]; instead the pancreatic cancer (PC) is the fourth
leading cause of cancer deaths among men and women,
being responsible for 6% of all cancer-related deaths [2], and
ﬁnally, the colorectal cancer (CRC) accounted for 9% of all
cancer deaths (49, 920) in 2009 [3].
For all these gastrointestinal cancers, surgical tumor
resection remains the primary curative treatment but the
overall 5-year survival rate remains poor, ranging between
20–25%[4–6].Theadditionofcombinedmodalitystrategies
(pre- or postoperative chemoradiotherapy or perioperative
chemotherapy) results in 5-year survival rates of only 30–
35% [7–9].
Therefore, many investigators believe that the potential
for making signiﬁcant progress lie on understanding and
exploiting the molecular biology of gastrointestinal tumors
to investigate new therapeutic strategies such as gene therapy
[10] and especially speciﬁc immunotherapy [11–13].
Evidence from diﬀerent analysis suggests a key role of
the immune system in counterattack of cancer progression:
tumors are 100 times more likely to occur in people who take
immunosuppressivemedicationsthaninpeoplewithnormal
immune function [14], and, in opposition, heightened anti-
tumor activity of the immune system has been suggested in
many reports of spontaneous cancer regression [15]. Also, a
positive correlation between tumor-inﬁltrating lymphocytes
and patients’ survival has been observed [16]; moreover
tumor-speciﬁc T-cell responses have been found in patients
with a variety type of tumors [17].
Immune defence against tumor is mediated through
antigen-speciﬁc and nonspeciﬁc immune mechanisms (ma-
crophage and NK cell lineage and soluble factors such as
cytokines). The operational, instead, of the antigen-speciﬁc
immunesystemisbasedonadivisionoftasksbetweenTcells
and B cells (Figure 1).
Various reagents (vaccines, infusion of T cells, or cytok-
ines) can stimulate the immune system essentially through2 Clinical and Developmental Immunology
two mechanisms: (1) stimulation of the antitumor response,
either by increasing the number of eﬀector cells or by
producing soluble mediators (e.g., cytokines); (2) alteration
of tumor cells to increase their immunogenicity and sus-
ceptibility to immunological defences. However, the cancer
cells have developed a number of diﬀerent strategies to
escape immune surveillance such as loss of tumor antigen
expression, MHC downregulation, expression of Fas-L that
can induce apoptosis in activated T cells, secretion of
cytokines such as IL-10 (Interleukin-10) or TGF-β (Tumor
grow factor-β), or generation of regulatory T (Treg) cells
[18].
The requirement for an immune-based strategy in oppo-
sitiontocanceristheinductionofaneﬀectivetumor-speciﬁc
immunity in order to break immunological tolerance to the
tumor and generate antitumor immunity. To achieve this
goal, several strategies as in preclinical models as in clinical
trials are currently being investigated.
In this paper we will focus on recent knowledge concern-
ing the role of T cells and the use of T adoptive immuno-
therapy in the treatment of gastrointestinal cancers.
2. PancreaticCancer
2.1. In Human and Animal Model T-Cell Response. Over the
past 30 years, a large body of data has been accumulated
showing that cancer patients generate B and T cells speciﬁc
to antigens expressed on autologous pancreatic tumor cells
[19–25]. PC expresses a variety of cancer-associated antigens
that can potentially be recognized by T cells [26, 27].
Recent studies demonstrated that functionally competent
CD4+ and CD8+ T cells with speciﬁcity for cancer antigens
are spontaneously induced in the bone marrow of all PC
patients [27, 28]. Moreover, in approximately 50% of the
patients, these tumor-speciﬁc T cells are also present in
the blood. Upon speciﬁc stimulation they mainly secrete
the type 1 cytokine IFN-γ, which is typical of cytotoxic
immune responses. The high incidence of spontaneous T-
cell reactivity versus PC is in contrast to observations from
numerous other cancer entities that induced cancer-reactive
T cells only in 25–60% of the patients [29–31].
T-cell responses are regulated by dendritic cells (DCs),
which constantly take up antigens in all tissues and upon
in situ activation, stimulate naive T cells. While type I
interferons, heat shock proteins, and extracellular matrix
degradation products may induce DC activation in can-
cer tissues, immune-suppressive cytokines (IL-10/TGF-β)
inhibit DC activation, and in PC the latter are produced
at high concentrations by cancer-induced pancreatic stellate
cells, cancer-inﬁltrating macrophages and mast cells [32], or
Tregs [33]. Through recruitment and activation of stroma
cell populations, PC generates a predominantly immune-
suppressive microenvironment (Figure 2).
The regular induction of T-cell responses in the bone
marrow of PC patients is thus intriguing.
The bone marrow is a site of T-cell priming against
blood-borne antigens [34]. It can collect soluble cancer
antigens released into the blood from necrotic cancer areas.
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Figure 1: Innate and adaptive immune defence against cancer cells.
Here, these are incorporated and presented by bone marrow-
resident DCs in an immune-stimulatory environment. In
addition, disseminated neoplastic cells detectable in many
patients represent a local source of cancer antigens [28].
PC is frequently diagnosed at late stages. In this situa-
tion, large antigen amounts may reach the bone marrow.
This might explain the comparably high incidence of T-
cell responses in PC despite a predominantly immune-
suppressive environment in the primary cancer. Once stim-
ulated, T cells diﬀerentiate into eﬀector T cells and enter
the blood. Since cancer-reactive T cells have been found in
the blood of many PC patients, these cells may inﬁltrate
pancreatic carcinomas.
In one study, cancer-reactive CD8+ T cells speciﬁcally
lysed autologous PC cells in vitro and delayed progression of
xenotransplanted, autologous carcinomas [27]. Accordingly,
increased numbers of cancer-inﬁltrating CD4+ and CD8+ T
cells correlated well with improved prognosis of PC patients
[35].
These ﬁndings point to a potential implication of cancer-
speciﬁc T cells during cancer progression, but PC cells
successfully employ various mechanisms to evade immune
surveillance (Figure 2): (a) the downregulation of MHC
moleculesandoffasreceptor,renderingneoplasticcellsmore
resistant to recognition and cytolysis by activated eﬀector
T cells [27], (b) the recruitment and local maintenance of
Tregs [36]that inhibit eﬀectorT-cellactivationandfunction,
(c) the secretion of IL-10 and TGF-β, additionally reducing
local T-cell activity [27, 37], (d) the inactivation of cancer-
inﬁltrating T cells as shown by a severe loss of CD3 zeta,
[37] and (e) the expression of fas ligand on neoplastic cells,
inducing apoptosis in cancer-inﬁltrating eﬀectorT cells [38].
Thus, PC is not characterized by a lack of speciﬁc T-
cell immunity but by a potent barrier established by com-
plex cancer-stroma interactions that inhibit T-cell activity
in situ; for this purpose is most explanatory the recent
results obtained by De Monte et al. [39]; they showed that
thymicstromallymphopoietin(TSLP),whichfavorsTh2cell
polarization through myeloid DC conditioning, was secreted
by cancer-associated ﬁbroblasts (CAFs) after activation with
tumor-derivedTNF-αandIL-1β.Alsotheauthorsfoundthat
the ratio of GATA-3+(Th2)/T-bet+ (Th1) tumor-inﬁltrating
T cells is an independent predictive marker of patientClinical and Developmental Immunology 3
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Figure 2: Pancreatic cancer microenvironment: interactions of immune cells with the cancer cells. Yellow: products of stellate cells; green:
T - c e l ld e r i v e dc y t o k i n e s ;g r e y :c a n c e rc e l l - d e r i v e df a c t o r s .
survival. Patients surgically treated for stage IB/III disease
with a ratio inferior to the median value had a statistically
signiﬁcantprolongedoverallsurvival,implyinganactiverole
for Th2 responses in disease progression.
In addition, in a mouse model in which an activating
K-Ras mutation is expressed in the pancreas, preinvasive
pancreatic lesions are characterized by the inﬁltration of
immune suppressor cells rather than immune eﬀector cells,
suggesting that tumor immunity may be blocked from the
inception of PC development [40].
All mice with the K-Ras mutation develop pancreatic
adenocarcinoma and eventually die of disease. Finally, the
ﬁnding that antagonism of negative T-cell regulators, such
as cytotoxic T-lymphocyte-associated (CTLA) protein-4 and
B- and T-lymphocyte attenuator (BTLA), can augment the
antitumor immune response conﬁrms that patients mount
animmune-speciﬁcresponsetotheirtumor[41,42].Despite
mounting evidence that an antitumor immune response is
elicited in cancer patients, this response is ineﬀective and
does not result in the tumor eradication, and a better under-
standing of the mechanisms underlying these interactions is
required to develop future therapeutic strategies to employ
the patient’s own T-cell arsenal for eﬃcient cancer control.
2.2. T-Cell Immunotherapy of Pancreatic Cancer. The history
of vaccine trials in pancreatic cancer targeting a deﬁned
PC antigen started with the publication of a pilot study
of mutant ras peptide vaccines tailored to represent the
K-RAS mutations identiﬁed in biopsies from the patients
with cancer [43] In this trial, immune responses speciﬁc
for individual ras mutations were obtained in 2 of the 5
patients enrolled; in addition, both patients had a relatively
long survival (11 and 8 months). These data shown that:
(a) patients with metastatic PC were immunocompetent, (b)
mutant ras vaccines were immunogenic, and (c) immune
responses were correlated with survival. Furthermore, the
treatment was well tolerated as no adverse eﬀects were
observed. A ﬁne evaluation of the immune responses in
these two patients [44] highlighted that peptide vaccination
with a single mutant p21-ras-derived peptide induced CD4+
and CD8+ speciﬁc for nested epitopes, including the Gly/Val
substitution at codon 12 and that both these T-cell subsets
speciﬁcally recognize tumour cells owning to the corre-
sponding K-ras mutation. Encouraged by these results, a
secondtrialwasperformed,usingintradermalvaccinationof
mutantraspeptideswithGMCSF(Granulocyte-macrophage
colony-stimulating factor) as an adjuvant [45]. 48 patients
(10 surgically resected and 38 with advanced disease) were
treated on an outpatient basis. Peptide-speciﬁc immunity
was induced in 25 of 43 (58%) evaluable patients, indicating
that the protocol used is very potent and able to elicit
immune responses even in patients with end-stage disease.
This study also demonstrated a strong association between
immune responses and prolonged survival. Patients with
advanced cancer and with immune response to the peptide
vaccine showed prolonged survival from the start of treat-
ment compared to nonresponders (median survival 148 days
versus 61 days). Furthermore, the study proved long-term
memory in numerous patients and entry of vaccine-speciﬁc
T cells into the tumour mass.4 Clinical and Developmental Immunology
In recent years, much work has focused on adoptive
tumor immunotherapy in which the T cells of cancer patient
are expanded and reinfused into the patient.
One method results in the selective expansion of T
cells endogenously expressing TCRs speciﬁc for the tumor
antigen of interest [46]. In a clinical study, MUC-1-speciﬁc
autologous T cells, isolated from patient PBMCs (peripheral
blood mononuclear cells), were expanded by incubation
with a MUC-1-presenting cell line prior to administration
to PC patients. The mean survival time for unresectable
patients in this study was 5 months [47]. However, patients
with resectable pancreatic cancer had 1-, 2- and 3-year
survival rates of 83.3, 32.4, and 19.4%, respectively, and a
mean survival time of 17.8 months. In a similar study, the
same group isolated adherent cells from patient PBMCs to
generate mature DCs that were then pulsed with MUC-
1 peptide. The pulsed DCs were administered, along with
autologous expanded MUC-1-speciﬁc T cells, to patients
with unresectable or recurrent pancreatic cancer. Remark-
ably, a complete response was observed in one patient with
lung metastases, and the mean survival time of the whole
group was 9.8 months, suggesting that the addition of pulsed
DCs may have improved the outcome [48].
A key role in future immunotherapeutic treatment of
PC patients seems to be for the novel antigen PC-associated
α-enolase (ENOA), a metabolic enzyme involved in the
synthesis of pyruvate. In tumor cells, ENOA is upregulated
and supports anaerobic proliferation (Warburg eﬀect); also,
it is expressed at the cell surface, where it promotes cancer
invasion.ENOAisupregulatedindiﬀerenttumors,including
brain, breast, cervix, colon, gastric, kidney, lung ovary, and
especially pancreas [49].
In pancreatic cancer, ENOA elicits a CD4+ and CD8+
T-cell response both in vitro and in vivo [49]. Anti-
MHC class I antibodies inhibited the cytotoxic activity of
ENOA-stimulated CD8+ T lymphocytes against PC cells,
but no MHC class I restricted peptide of ENOA has been
identiﬁed so far. Moreover, in pancreatic ductal adenocarci-
noma patients, production of anti-ENOA Immunoglobulin-
G (IgG) is correlated with the ability of T cells to be
acti v a t e di nr e s po n s et ot h ep r o t e i n[ 49], thus conﬁrming the
induction of a T- and B-cell integrated antitumor activation
against ENOA. In oral squamous cell carcinoma, an HLA-
DR8-restricted peptide (amino acid residues 321–336) of
human ENOA recognized by CD4+ T cells and able to confer
cytotoxic susceptibility has been identiﬁed [50, 51].
Most importantly, clinical correlations [52–54]p r o p o s e
ENOA as a novel target for cancer immunotherapy, in par-
ticular in pancreatic cancer, where pancreas-speciﬁc Ser 419
phosphorylated ENOA is upregulated and also induces the
productionofautoantibodieswithdiagnosticandprognostic
value [49].
3.GastricCancer
3.1. Gastric Cancer-Inﬁltrating T Cells . Although the GC eti-
ology has been completely obscure for many decades, several
considerableadvancesintheknowledgeofthecarcinogenesis
and development of gastric cancer have been made in the
present era. First, it is well known that Helicobacter pylori
(H.pylori)infectionisassociatedwiththeGCcarcinogenesis,
suggesting that chronic inﬂammation may be implicated in
the development of intestinal metaplasia and mutations in
oncogenes that precede the GC development; indeed, the
International Agency for Research on Cancer classiﬁed H.
pyloriasaclassIhumancarcinogenin1994[55].Second,the
long-suspected inﬂuence of genetic susceptibility has been
elucidated, and several polymorphisms of inﬂammatory
cytokinegeneshavebeenimplicatedasriskfactorsforgastric
cancer [56–60].
Although immune cells constitute an additional and
prominent component of the host response to cancer, their
participation in tumor pathogenesis remains unclear. In the
tumormicroenvironment,thereisadelicatebalancebetween
antitumor immunity and tumor-originated proinﬂamma-
tory activity, which weakens antitumor immunity [61–63].
It has been shown that the inﬁltrating grade of CD3+
tumor-inﬁltrating lymphocytes (TILs) was correlated with a
favorable outcome in patients with several types of cancer,
including gastric cancer [64]. Thus, it is imperative to
understand immunoregulation in gastric cancer, in order to
develop novel treatment strategies or improve the eﬃcacy of
standard therapies.
The ﬁrst evidence of correlation between T-cell response
and GC was the study of Ren et al. [65] that reported a
shift from Th1 to Th2 pattern of cytokine secretion in gastric
cancer and has suggested that this may be a critical factor in
promotinggrowthofneoplasticcells.However,ourdata[66]
of tumor-inﬁltrating and perilesional H. pylori-speciﬁc T
cellsfailedtoconﬁrmsuchaTh1-Th2shift.Rather,themajor
diﬀerence between the gastric T-cell clones from uncom-
plicated chronic gastritis and those from gastric cancer was
the degree of expression of cytolytic activity. Indeed, in all
patients studied, virtually all the H. pylori-speciﬁc CD4+
clones derived from gastric tumors or perilesional mucosa
consistently expressed perforin-mediated cytolytic potential
and Fas-Fas ligand-mediated proapoptotic activity against
target cells.
Most recently, Maruyama et al. [67] investigated the
distribution of Th17 (T helper 17) cells in relation to Treg
as in the TILs as in peripheral blood of GC patients. They
showed that in TILs from patients with early disease, the
frequency of Th17 cells was signiﬁcantly higher than that in
the normal gastric mucosa (23.7 ± 8.9 versus 4.5 ± 3.1%).
Besides, in TILs from patients with advanced disease (n =
28), the frequency of Th17 cells was also signiﬁcantly higher,
but lower compared to early disease, than that in the normal
gastric mucosa (15.1 ± 6.2 versus 4.0 ± 2.0%). When the
ratio of Th17/Treg in TILs was evaluated in individual cases,
it was more markedly increased in early than in advanced
disease.
In summary, the accumulation of Th17 cells as well
as Tregs in the tumor microenvironment of gastric cancer
occurred in early disease, and then the inﬁltration of Th17
cells gradually decreased according to the disease progres-
sion, in contrast to increased Tregs.Clinical and Developmental Immunology 5
3.2. T-Cell-Based Antigastric Cancer Treatments. There are
diﬀerent types of T-cell-based anticancer therapy approach-
es, using (a) CTL, (b) TILs, or (c) Engineered T cells.
Improved CTL cell culture technology has permitted
the ﬁrst clinical tests for adoptive transfer of CTLs, and
this technique [68] seems to result in substantial activity in
patients with melanoma; CTLs were used to treat patients
with metastatic melanoma, and 8 out of 20 patients had anti-
tumor immune responses [68]. These results were conﬁrmed
in an independent trial in which engraftment of the CTLs,
as measured by an elevated frequency of circulating T cells
able to bind tetramers loaded with MART-1 peptides, was
detectable up to two weeks after T-cell transfer in all patients
[69].
Recently, Kim et al. [70] evaluated the antitumor activity
of ex vivo expanded T cells against the human gastric
cancer. For this purpose, human peripheral blood mononu-
clear cells were cultured with IL-2-containing medium in
anti-CD3 antibody-coated ﬂasks for 5 days, followed by
incubation in IL-2-containing medium for 9 days. The
resulting populations were mostly CD3+ T cells [97%] and
comprised 1% CD3−CD56+, 36% CD3+CD56+, 11% CD4+,
and 80% CD8+. This heterogeneous cell population was also
called cytokine-induced killer (CIK) cells. CIK cells strongly
produced IFN-γ,m o d e r a t e l yT N F - α, but not IL-2 and IL-4.
At an eﬀector-target cell ratio of 30:1, CIK cells destroyed
58% of MKN74 human gastric cancer cells, as measured
by the 51Cr-release assay. In addition, CIK cells at doses of
3 and 10 million cells per mouse inhibited 58% and 78%
of MKN74 tumor growth in nude mouse xenograft assays,
respectively. This study suggests that CIK cells may be used
as an adoptive immunotherapy for GC patients.
The adoptive GC immunotherapy with CIK cells has
been also reported in preclinical and clinical studies [71].
MHC-I restricted CTLs from GC patients recognize tumor-
associated antigen and react speciﬁcally against self-tumor
cells [72, 73]. One tumor-speciﬁc antigen, MG7-antigen,
shows great potential for predicting early cancer as well as
for inducing immune responses to GC [74, 75]. Using HLA-
A-matched allogeneic gastric cancer cells to induce tumor-
speciﬁc CTLs appears to be an alternative immunotherapy
option for gastric cancer [76].
Also, CIK cells in combination with chemotherapy
showed beneﬁts for patients who suﬀer from advanced gas-
tric cancers [77, 78]. The serum levels of the tumor markers
were signiﬁcantly decreased, the host immune function was
increased, and the short-term curative eﬀect, as well as the
quality of life, was improved in patients treated by chemo-
therapy plus CIK cells compared to those in patients treated
by chemotherapy alone. CIK cells killed MGC-803 GC cells
by inducing apoptosis in the early stage and by inducing
necrosis in the late stage through downregulation of p53, c-
myc, and bcl-2 and upregulation of bax [79].
In summary, despite the introduction of immune cell-
based immunotherapy, the paucity of preclinical and clinical
studies has limited the broad application of immunotherapy
for the treatment of GC patients with gastric cancers. Here,
preclinical evidence proved that CIK cell immunotherapy
can be used in patients with gastric cancer.
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Figure 3: Scheme of adoptive autologous TILs transfer. T-
inﬁltrating lymphocytes can be isolated from resected surgical
samplesandexpandedinvitroforadoptivetransferafterlymphode-
pleting chemotherapy. Most adoptive transfer therapy approaches
using TILs have involved the use of IL-2 infusion following T-cell
transfer in order to select tumor-speciﬁc T cells.
AdoptivetransfertherapywithTILsrequirestheisolation
of T cells from neoplastic biopsies or surgical tissue and the
selection of tumor-speciﬁc T cells ex vivo (Figure 3). The
adoptive transfer of TILs has been promising in preclinical
models [80], but clinical experiences were almost uniformly
disappointing [81, 82].
Technical diﬃculties in producing tumor-speciﬁc T
cells currently represent a barrier to randomized clinical
trials. Only 30%–40% of the biopsies yield satisfactory T-
cell populations, and the whole process requires about 6
weeks before the T cells would be ready for infusion [83].
Furthermore, nearly all clinical experiences with TILs have
been done in patients with melanoma, because of the easy
surgical availability of the tumor tissue. However, should
technical limitations of current tissue culture approaches
be overcome, recent studies indicate that the presence of
TILs positively correlates with patients survival in ovarian
and colorectal cancer [84, 85], thus prompting the use of
this protocol for other commonly encountered epithelial
neoplasias. Recently we have [11] analyzed the functional
properties of the T-cell response to diﬀerent antigen peptides
related to GC in patients with gastric adenocarcinoma. To
this purpose, we have cloned and characterized TILs isolated
from the neoplastic gastric tissue samples. A T-cell response
speciﬁc to diﬀerent peptides of gastric cancer antigens tested
was documented in 17 out of 20 patients, selected for
their HLA-A02 and/or -A24 alleles. Most of the cancer
peptide-speciﬁc TILs expressed a Th1 proﬁle and cytotoxic
activity against target cells. The eﬀector functions of cancer
peptide-speciﬁc T-cells obtained from the peripheral blood
of the same patients were also studied, and the majority of
peripheral blood peptide-speciﬁc T cells also expressed the
Th1 functional proﬁle.
In conclusion, in most of patients with gastric adenocar-
cinoma, a speciﬁc type-1 T-cell response to GC antigens was6 Clinical and Developmental Immunology
detectable and would have the potential of hamper tumor
cell growth. However, in order to get tumor cell killing in
vivo, the activity and the number of cancer peptide-speciﬁc
Th1 cells probably need to be enhanced by vaccination with
the appropriate cancer antigenic peptides or by injection
of the autologous tumor peptide-speciﬁc T cells expanded
in vitro. These studies have laid the groundwork for a
possible vaccination of gastric adenocarcinoma patients with
speciﬁc peptides of tumor-associated antigens able to raise
an eﬀective immune response to gastric cancer.
4. Colorectal Cancer
4.1. Tumour-Inﬁltrating T-Cell Subsets in Colorectal Cancer.
In recent years, diﬀerent studies demonstrated the presence
of T cell into neoplastic tissue of colorectal patients and
also that the type, location, and density of tumor-inﬁltrating
immune cells are of strong predictive impact inﬂuencing
the behavior of human CRC [85, 86]. Although the exact
mechanism remains uncertain, the adaptive immune system
plays an important role in suppressing tumour progression
[87, 88]. In the Table 1 we resumed the major studies
correlating the TIL subsets and survival of CRC patients.
From the above, the tumour-inﬁltrating T cells may be at
thesametime,anindicatorofthehostimmuneresponsever-
sus cancer cells and an attractive target for immunotherapy
[18, 89, 90].
The TILs may also reﬂect speciﬁc molecular alterations
associated with indolent tumour behaviour. Previous studies
have shown that lymphocytic inﬁltration is associated with
microsatellite instability (MSI) in colorectal cancer [91–
93]. Truncated peptides produced by frameshift mutations
d u et oM S Im a yb ei m m u n o g e n i ca n dc o n t r i b u t et ot h e
host immune response [88, 89, 94]. However, at the time,
very little is known about the interrelationship between
TILs, MSI, and other tumour molecular features, such as
the CpG island methylator phenotype (CIMP), global DNA
hypomethylation,andKRAS,BRAF,andPIK3CAmutations.
Previous studies have reported that MSI [95], CIMP
[96], BRAF mutation [97], PIK3CA mutation [98], and
tumour LINE-1 hypomethylation [99] are associated with
prognosis and that lymphocytic inﬁltration is associated
with many of these molecular variables [92]. As such, to
deﬁne the prognostic eﬀect of tumour-inﬁltrating T cells
independently of those potential confounders, large studies
of colorectal cancers with extensive molecular characteri-
zation are needed. Most recently, Nosho and coll. [100],
using a database of 768 colorectal cancers, analyzed the
subsets of TILs in relation with molecular changes in
patients with CRC. They demonstrated that the densities of
CD8+, CD45RO+,a n dF O X P 3 + cells were signiﬁcantly asso-
ciated with patient survival in univariate analyses (P trend
< 0.007). In the multivariate model, tumour-inﬁltrating
CD45RO+-cell density, but not CD3+,C D 8 +,o rF O X P 3 +-
cell density, was signiﬁcantly associated with survival (P =
0.0032). In multivariate linear regression analysis, MSI-high
(P<0.0001) and high-level tumour LINE-1 methylation
(P = 0.0013) were independently associated with higher
CD45RO+-cell density. The survival beneﬁt associated with
CD45RO+ cells was independent of MSI and LINE-1 status.
In conclusion, tumour-inﬁltrating CD45RO+-cell density is
a prognostic biomarker associated with longer survival of
colorectal cancer patients, independent of clinical, patho-
logical, and molecular features. In addition, MSI-high and
tumourLINE-1methylationlevelareindependentpredictors
of CD45RO+-cell density. These results oﬀer a possible
mechanism by which MSI confers an improved clinical
outcome and support eﬀorts to augment the host immune
response in the cancer microenvironment as a strategy of
targeted immunotherapy.
As with all tumors analyzed so far, even for the CRC
it is very important to evaluate the impact of Tregs on the
speciﬁc immune responses against tumor-associated anti-
gens (TAAs). The grade of local inﬁltration did not correlate
with responses against well-deﬁned TAAs as EpCAM, Her-
2/neu, and CEA [101]. Depleting Tregs in PBMCs from
CRC patients dramatically boosted the IFN-γ and TNF-α
production in T cells, which were stimulated with a CEA
peptide [102]. In spite of the unmasking of responses in
opposition to other TAAs, recall antigens such as PPD were
not aﬀected suggesting a TAA-speciﬁc rather than a systemic
immune suppression [103].
In an extremely ample analysis various TAA-speciﬁc
Tregs were exclusively identiﬁed in CRC patients. Peptides
for CEA, telomerase, Her-2/neu, and MUC-1 all led to
an activation of Tregs [104]. TAA-speciﬁc Tregs were suc-
cessfully identiﬁed using a p53 peptide [105]; in addition
to CD4+ Tregs also CD8+CD28− Tregs could be isolated
from peripheral blood, tumor tissue, and metastatic lymph
nodes of CRC patients [106]. These cells suppressed T cells
in an IL-10-dependent fashion and were mainly CD194+,
which may have contributed to their accumulation via
recruitment.Arecentstudyidentiﬁedcirculatingandtumor-
inﬁltrating CD28+CD8+ Tregs with a CD25+,F O X P 3 +,
CD152+,G I T R +, CD194+,T G F - β+, and CD127− phenotype
[107]. Remarkably this type of Tregs was found in 90%
of the CRC specimens but was totally absent in normal
colonic tissue suggesting a cancer-speciﬁc presence without
contribution to the physiologic epithelial homeostasis [108].
Ligands for CD194 (e.g., CCL17 or CCL22) were in contrast
to IL-6 and TGF-β not highly expressed in the tumor tissue,
altogether indicating a conversion from CD8+ rather than
a tumor-directed migration as the cause for the observed
inﬁltration. In another recent study CXCL11 produced by
CRC-derived CD68+ myeloid cells is suggested to be a
promising chemoattractant for Tregs [109].
4.2. T-Cell-Based Immunotherapy in CRC Patients. T-cell-
based immunotherapy (TCI) was ﬁrst described in 1988
[110], but the decisive improvement in eﬃcacy came in 2002
with the introduction of an immunodepleting preparative
regimen given before the adoptive transfer, which could
result in the clonal repopulation of patients with antitumour
T cells [111]. Of patients with metastatic melanoma refrac-
tory to all other treatments, 50% will experience an objective
response, some with complete responses [112]. Responses
can be durable and are seen in all organ sites, including
the brain. Recent studies demonstrating that normal humanClinical and Developmental Immunology 7
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T cell can be genetically engineered to recognize cancer
antigens and mediate cancer regression in vivo have opened
opportunitiesforenhancingandextendingtheTCIapproach
to patients with a wide variety of cancer types [113]. These
studies provide a valuable guide to the immunological
principlesthatformthebasisofeﬀectiveimmunotherapyfor
CRC patients.
Most nonhematopoietic tumors such as CRC express
MHC class I molecules, but do not express MHC class
II molecules, therefore it is believed that the predominant
tumor-speciﬁc cell-mediated immune eﬀector mechanism is
thekillingbyCTL.However,theclinicalhistoryofthepatient
with cancer often demonstrates the failure of the immune
system to eliminate the tumor [114]. It is now generally
accepted that this is mostly due to poor tumor-speciﬁc MHC
classII-restrictedCD4+ T helpergeneratedin tumor-bearing
hosts [115–117] and that Th cells are required for priming
and clonal expansion of speciﬁc CTL following reencounter
with antigen [118–121].
Although at clinical level, TCI results are still prelimi-
nary [122], nevertheless the importance of including CD4+
together with CD8+ T cells to induce optimal therapeutic
eﬀects has been established [112, 123].
For this purpose and to optimize the antitumor
immunological arms in terms of speciﬁcity and long-lasting
memory, vaccination with tumor cells transduced with the
AIR-1-encoded CIITA, the MHC class II [MHC-II] gene
transactivator [124, 125], has been explored with the idea
that CIITA-transfected cells may act as “surrogate APC”
for optimal triggering of tumor-speciﬁc Th cells and thus
facilitate the recognition of TAA presented by tumor cell
MHC-II molecules. Indeed, the group of Accola showed
that complete rejection and long-lasting antitumor memory
could be obtained after vaccination with CIITA-expressing
TS/A mammary adenocarcinoma [126–128]; Most recently,
the same group [129] demonstrated that CIITA-expressing
C51 colon adenocarcinoma cells are rejected in high per-
centage of mice or strongly reduced in growth. Induction of
antitumor immunity depended on the ability of the MHC-
II-positive tumor cells to trigger CD4+ T cells, which in
turn induce stimulation and maturation of CTL eﬀectors.
Importantly, they showed that immune CD4+ Th cells can
induce protective antitumor responses in naive mice injected
with parental nontransfected tumor cells. Puriﬁed CD4+ T
cells from C51-CIITA vaccinated and challenged mice were
also eﬃcacious in preventing tumor growth of C51 tumor,
as 50% of the animals were protected and the remaining
50% displayed a signiﬁcant growth retardation. Similar
results were obtained when immune CD8+ Tc e l l sw e r e
used in adoptive transfer, even if CD4+ T cells were clearly
superior to CD8+ T cells in antitumor protective function.
Interestingly, the protective phenotype was associated to
both a Th1 and Th2 polarization of the immune eﬀectors.
In conclusion, these results demonstrated that tumor cell
modiﬁcation by CIITA may oﬀer an alternative strategy not
only for preventive vaccination but also for the generation of
more eﬃcacious TCI for CRC patients.
In recent years it has also become increasingly the cancer
stem cell theory [130], the idea that cancers are composed
of several types of cells, and that only a small population
of cancer cells that can regenerate cancer tissues, much as
normal tissue can be regenerated only by a small population
of stem-like cells. Recently, cancer stem-like cells and tumor-
initiating cells (CSCs/TICs) have been isolated from various
types of malignancies, including colon cancer [131–135].
In colon cancer, CSCs/TICs can reinitiate tumors that
resemble mother colon cancer tissues morphologically when
transplanted into immunodeﬁcient mice [132]. Further-
more, these CSCs/TICs have higher tumorigenic potential
thandonon-CSCs/TICs,suggestingthattheyareessentialfor
tumor maintenance and distant metastasis [132].
Previous reports have shown that CSCs/TICs are resis-
tant to a variety of treatments, including chemotherapy
and radiotherapy, with varied mechanisms of resistance,
including high expression of drug transporters, relative cell
cycle quiescence, high levels of DNA repair machinery, and
resistance to apoptosis [136].
In recent times Inoda and coll. shown that CTL speciﬁc
for the tumor-associated antigen CEP55 can eﬃciently
recognize colon CSCs/TICs both in vitro and in vivo.T h e
authors isolated CSCs/TICs as side population (SP) cells
from colon cancer cell lines SW480, HT29, and HCT15. The
SP cells expressed high levels of the stem cell markers SOX2,
POU5F1, LGR5, and ALDH1A1 and shown resistance to
chemotherapeuticagents(irinotecanoretoposide).Toevalu-
ate the susceptibility of SP cells to CTLs, they used CTL clone
41, which is speciﬁc for the CEP55-derived antigenic peptide
Cep55/c10orf3 193 [137, 138]. The SP cells expressed HLA
class I and CEP55 at the same level as the main population
cells. The SP cells were susceptible to CTL clone 41 at the
same level as main population cells. Furthermore, adoptive
transfer of CTL clone 41 inhibited tumor growth of SW480
SP cells in vivo.
These results suggest that Cep55/c10orf3 193 [137, 138]
peptide-based cancer vaccine therapy or adoptive cell trans-
fer of the CTL clone is a possible approach for targeting
chemotherapy-resistant colon CSCs/TICs.
5. Conclusion
Despite advances in clinical diagnostics, surgical techniques,
and development of new chemo/radiotherapy regimens the
prognosis of gastrointestinal oncology remains poor, and the
need for new treatment options, such as immunotherapy, is
imperative.
Studies of T-cell-based immunotherapy have clearly
demonstrated that the administration of highly avid anti-
tumour T cells directed against a deﬁned target can mediate
the regression of large, vascularized, metastatic cancers and
provide guiding principles as well as encouragement for the
further development of adoptive T-cell therapy for cancer
patients.
In this paper we have reported the evidence of the key
role of T-cell response versus cancer of the digestive system
and the results obtained in diﬀerent clinical trials using T-
cell immunotherapy.
We showed that for pancreatic cancer as well as for both
gastric and colorectal cancer good results were obtained12 Clinical and Developmental Immunology
in some clinical settings but in order that T-cell-based
immunotherapy become a real treatment for gastrointestinal
oncology, several problems must be solved.
A major problem with the application of TCI is that it
is a highly personalized treatment and does not easily ﬁt
into current modes of oncological practice. The treatment
is expensive, labour-intensive, and requires high laboratory
expertise. In essence, a new reagent needs to be created for
eachpatient,andthispatient-speciﬁcnatureofthetreatment
makes it diﬃcult to commercialize.
Moreover, currently the major challenge in the ﬁeld is to
conduct randomized clinical trials demonstrating suﬃcient
clinical beneﬁt to justify the logistics and costs of customized
cellulartherapies.Inmanyclinicaltrials,patientsareenrolled
at an advanced cancer stage, and this aspect could determine
an unfavourable outcome; thus, it would be very interesting
to plan clinical trials in early-stage of cancer because it would
be possible that gastrointestinal cancer immunotherapeutic
approaches confer a survival advantage when applied earlier
during the course of the disease, such as in the adjuvant
setting.
However, the big hurdle to make immunotherapy ap-
proach successful for gastrointestinal oncology remains the
immune evasion strategies set up by the tumor resulting in
avoidance of both innate and adaptive immunity.
Investigations during the past few years have provided
new insights into the cellular and molecular mechanisms
involved in the bidirectional crosstalk between cancer cells
and the immune cells. Understanding this functional dia-
logue and the hierarchical status of diﬀerent tumor-immune
escape stratagems at diﬀerent stages of tumor development
will guide the design of novel therapeutic strategies aiming
to demolish the “tumor fortress”.
Thus, it will be of particular interest to study the kinetics
of the interactions between diﬀerent inhibitory molecules
and endogenous factors that inﬂuence the expansion and
traﬃcking of Tregs and tolerogenic DCs within tumor-
draining lymph nodes and the tumor surroundings.
On the basis of clinical and experimental evidence, it
is reasonable to conclude that successful therapy for gas-
trointestinaloncologymustinvolveacombinationapproach,
which should involve systemic chemotherapy and transplan-
tation to reduce the burden or to eliminate immune sup-
pressive cells, together with tailor-made immunotherapies
customized to each single patient.
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